110 related articles for article (PubMed ID: 27042010)
1. Selective CDK7 inhibition with BS-181 suppresses cell proliferation and induces cell cycle arrest and apoptosis in gastric cancer.
Wang BY; Liu QY; Cao J; Chen JW; Liu ZS
Drug Des Devel Ther; 2016; 10():1181-9. PubMed ID: 27042010
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and evaluation of thieno[3,2-d]pyrimidine derivatives as novel potent CDK7 inhibitors.
Zhang H; Lin G; Jia S; Wu J; Zhang Y; Tao Y; Huang W; Song M; Ding K; Ma D; Fan M
Bioorg Chem; 2024 Jul; 148():107456. PubMed ID: 38761706
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer.
Li B; Ni Chonghaile T; Fan Y; Madden SF; Klinger R; O'Connor AE; Walsh L; O'Hurley G; Mallya Udupi G; Joseph J; Tarrant F; Conroy E; Gaber A; Chin SF; Bardwell HA; Provenzano E; Crown J; Dubois T; Linn S; Jirstrom K; Caldas C; O'Connor DP; Gallagher WM
Cancer Res; 2017 Jul; 77(14):3834-3845. PubMed ID: 28455421
[TBL] [Abstract][Full Text] [Related]
4. Selective CDK7 Inhibition Suppresses Cell Cycle Progression and MYC Signaling While Enhancing Apoptosis in Therapy-resistant Estrogen Receptor-positive Breast Cancer.
Guarducci C; Nardone A; Russo D; Nagy Z; Heraud C; Grinshpun A; Zhang Q; Freelander A; Leventhal MJ; Feit A; Cohen Feit G; Feiglin A; Liu W; Hermida-Prado F; Kesten N; Ma W; De Angelis C; Morlando A; O'Donnell M; Naumenko S; Huang S; Nguyen QD; Huang Y; Malorni L; Bergholz JS; Zhao JJ; Fraenkel E; Lim E; Schiff R; Shapiro GI; Jeselsohn R
Clin Cancer Res; 2024 May; 30(9):1889-1905. PubMed ID: 38381406
[TBL] [Abstract][Full Text] [Related]
5. Discovery of novel co-degradation CK1α and CDK7/9 PROTACs with p53 activation for treating acute myeloid leukemia.
Wang K; Jiang M; Liu H; Meng C; Li M; Lu H
Bioorg Chem; 2024 Jun; 147():107319. PubMed ID: 38593529
[TBL] [Abstract][Full Text] [Related]
6. Transcriptional CDK inhibitors, CYC065 and THZ1 promote Bim-dependent apoptosis in primary and recurrent GBM through cell cycle arrest and Mcl-1 downregulation.
Juric V; Hudson L; Fay J; Richards CE; Jahns H; Verreault M; Bielle F; Idbaih A; Lamfers MLM; Hopkins AM; Rehm M; Murphy BM
Cell Death Dis; 2021 Aug; 12(8):763. PubMed ID: 34344865
[TBL] [Abstract][Full Text] [Related]
7. Unveiling the promise of pyrimidine-modified CDK inhibitors in cancer treatment.
Dubey R; Makhija R; Sharma A; Sahu A; Asati V
Bioorg Chem; 2024 Aug; 149():107508. PubMed ID: 38850781
[TBL] [Abstract][Full Text] [Related]
8. Design and Synthesis of Novel Macrocyclic Derivatives as Potent and Selective Cyclin-Dependent Kinase 7 Inhibitors.
Niu P; Tao Y; Lin G; Xu H; Meng Q; Yang K; Huang W; Song M; Ding K; Ma D; Fan M
J Med Chem; 2024 Apr; 67(8):6099-6118. PubMed ID: 38586950
[TBL] [Abstract][Full Text] [Related]
9. Cyclin-dependent kinase inhibitor therapy for hematologic malignancies.
Bose P; Simmons GL; Grant S
Expert Opin Investig Drugs; 2013 Jun; 22(6):723-38. PubMed ID: 23647051
[TBL] [Abstract][Full Text] [Related]
10. Cyclin-dependent kinase 7 (CDK7) inhibitors as a novel therapeutic strategy for different molecular types of breast cancer.
Song X; Fang C; Dai Y; Sun Y; Qiu C; Lin X; Xu R
Br J Cancer; 2024 May; 130(8):1239-1248. PubMed ID: 38355840
[TBL] [Abstract][Full Text] [Related]
11. Discovery of a Dual-Target Inhibitor of CDK7 and HDAC1 That Induces Apoptosis and Inhibits Migration in Colorectal Cancer.
Chen Y; Zhang S; Li Z; Yin B; Liu Y; Zhang L
ChemMedChem; 2023 Dec; 18(23):e202300281. PubMed ID: 37821774
[TBL] [Abstract][Full Text] [Related]
12. Active growth signaling promotes senescence and cancer cell sensitivity to CDK7 inhibition.
Wilson GA; Vuina K; Sava G; Huard C; Meneguello L; Coulombe-Huntington J; Bertomeu T; Maizels RJ; Lauring J; Kriston-Vizi J; Tyers M; Ali S; Bertoli C; de Bruin RAM
Mol Cell; 2023 Nov; 83(22):4078-4092.e6. PubMed ID: 37977119
[TBL] [Abstract][Full Text] [Related]
13. CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma.
Yao Y; Ng JF; Park WD; Samur M; Morelli E; Encinas Mayoral J; Chyra Z; Xu Y; Derebail S; Epstein C; Nabet B; Chesi M; Gray NS; Young RA; Kwiatkowski N; Mitsiades C; Anderson KC; Lin CY; Munshi NC; Fulciniti M
Blood; 2023 Jun; 141(23):2841-2852. PubMed ID: 36877894
[TBL] [Abstract][Full Text] [Related]
14. CDK7 in breast cancer: mechanisms of action and therapeutic potential.
Gong Y; Li H
Cell Commun Signal; 2024 Apr; 22(1):226. PubMed ID: 38605321
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic effects of antimicrobial peptide on malignant ascites in a mouse model.
Xia LJ; Wu YL; Ma J; Zhang FC
Mol Med Rep; 2018 May; 17(5):6245-6252. PubMed ID: 29512744
[TBL] [Abstract][Full Text] [Related]
16. Starving multiple myeloma cells via CDK7 inhibition.
Sacco A; Roccaro AM
Blood; 2023 Jun; 141(23):2787-2788. PubMed ID: 37289477
[No Abstract] [Full Text] [Related]
17. Protein engineering enables a soakable crystal form of human CDK7 primed for high-throughput crystallography and structure-based drug design.
Mukherjee M; Day PJ; Laverty D; Bueren-Calabuig JA; Woodhead AJ; Griffiths-Jones C; Hiscock S; East C; Boyd S; O'Reilly M
Structure; 2024 Jun; ():. PubMed ID: 38870939
[TBL] [Abstract][Full Text] [Related]
18. Targeting super-enhancer-associated oncogenes in oesophageal squamous cell carcinoma.
Jiang YY; Lin DC; Mayakonda A; Hazawa M; Ding LW; Chien WW; Xu L; Chen Y; Xiao JF; Senapedis W; Baloglu E; Kanojia D; Shang L; Xu X; Yang H; Tyner JW; Wang MR; Koeffler HP
Gut; 2017 Aug; 66(8):1358-1368. PubMed ID: 27196599
[TBL] [Abstract][Full Text] [Related]
19. Triptolide Induces Cell Killing in Multidrug-Resistant Tumor Cells via CDK7/RPB1 Rather than XPB or p44.
Yi JM; Huan XJ; Song SS; Zhou H; Wang YQ; Miao ZH
Mol Cancer Ther; 2016 Jul; 15(7):1495-503. PubMed ID: 27197304
[TBL] [Abstract][Full Text] [Related]
20. Strategically targeting MYC in cancer.
Posternak V; Cole MD
F1000Res; 2016; 5():. PubMed ID: 27081479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
